NEW YORK – Roche Diagnostics announced on Tuesday that its Elecsys Anti-SARS-CoV-2-S test has received approval under Health Canada's Interim Order.
The immunoassay qualitatively and semi-quantitatively measures the level of antibodies against the viral spike protein of SARS-CoV-2 from a blood sample in people who have either been exposed to the virus or vaccinated. It can help clinicians determine potential immunity and vaccine efficacy, Roche said in a statement.